Corvus Pharmaceuticals (CRVS) Common Equity (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Common Equity of $240.7 million for Q1 2026, up 387.95% year-over-year from $49.3 million in Q1 2025, and up 293.23% quarter-over-quarter from $61.2 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Common Equity (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $240.7 million for Q1 2026.
- In Q1 2026, Common Equity rose 387.95% year-over-year to $240.7 million; the TTM figure through Mar 2026 stood at $240.7 million (up 387.95% YoY), while the FY2025 annual figure was $61.2 million, up 87.93% from the prior year.
- Common Equity for Q1 2026 stood at $240.7 million, up from $61.2 million in the prior quarter.
- The five-year high for Common Equity was $240.7 million in Q1 2026, with the low at $12.4 million in Q3 2024.
- The 5-year median for Common Equity is $51.2 million (2024), against an average of $65.0 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 71.98% in 2024, then soared 478.35% in 2025.
- Corvus Pharmaceuticals' Common Equity stood at $56.1 million in 2022, then tumbled by 31.06% to $38.7 million in 2023, then declined by 15.81% to $32.6 million in 2024, then soared by 87.93% to $61.2 million in 2025, then soared by 293.23% to $240.7 million in 2026.
- Business Quant data shows CRVS's Common Equity at $240.7 million in Q1 2026, $61.2 million in Q4 2025, and $71.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 225.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 225.33 Mn |
| Mar 31, 2026 | 240.68 Mn |
| Dec 31, 2025 | 61.21 Mn |
| Sep 30, 2025 | 71.77 Mn |
| Jun 30, 2025 | 80.23 Mn |
| Mar 31, 2025 | 49.33 Mn |
| Dec 31, 2024 | 32.57 Mn |
| Sep 30, 2024 | 12.41 Mn |
| Jun 30, 2024 | 51.23 Mn |
| Mar 31, 2024 | 33.36 Mn |
| Dec 31, 2023 | 38.68 Mn |
| Sep 30, 2023 | 44.29 Mn |
| Jun 30, 2023 | 49.48 Mn |
| Mar 31, 2023 | 48.87 Mn |
| Dec 31, 2022 | 56.12 Mn |
| Sep 30, 2022 | 64.68 Mn |
| Jun 30, 2022 | 80.39 Mn |
| Mar 31, 2022 | 89.72 Mn |
| Dec 31, 2021 | 97.16 Mn |
| Sep 30, 2021 | 105.15 Mn |